

## Review Article

# Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review

Sarah Mousavi,<sup>1</sup> Mandana Moradi,<sup>2</sup> Tina Khorshidahmad,<sup>3</sup> and Maryam Motamedi<sup>3</sup>

<sup>1</sup>Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>2</sup>Faculty of Pharmacy, Zabol University of Medical Sciences, Zabol, Iran

<sup>3</sup>Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Sarah Mousavi; [s.mousavi@pharm.mui.ac.ir](mailto:s.mousavi@pharm.mui.ac.ir)

Received 24 February 2015; Accepted 24 April 2015

Academic Editor: Berend Olivier

Copyright © 2015 Sarah Mousavi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Heparin, used clinically as an anticoagulant, also has anti-inflammatory properties. The purpose of this systematic review was to provide a comprehensive review regarding the efficacy and safety of heparin and its derivatives as anti-inflammatory agents. **Methods.** We searched the following databases up to March 2012: Pub Med, Scopus, Web of Science, Ovid, Elsevier, and Google Scholar using combination of Mesh terms. Randomized Clinical Trials (RCTs) and trials with quasi-experimental design in clinical setting published in English were included. Quality assessments of RCTs were performed using Jadad score and Consolidated Standards of Reporting Trials (CONSORT) checklist. **Results.** A total of 280 relevant studies were reviewed and 57 studies met the inclusion criteria. Among them 48 studies were RCTs. About 65% of articles had score of 3 and higher according to Jadad score. Twelve studies had a quality score > 40% according to CONSORT items. Asthma ( $n = 7$ ), inflammatory bowel disease ( $n = 5$ ), cardiopulmonary bypass ( $n = 8$ ), and cataract surgery ( $n = 6$ ) were the most studied disease condition. Forty studies use unfractionated heparin (UFH) for intervention; the remaining studies use low molecular weight heparin (LMWH). **Conclusion.** Despite the conflicting results, heparin seems to be a safe and effective anti-inflammatory agent; although it is shown that heparin can decrease the level of inflammatory biomarkers and improves patient conditions, still more data from larger rigorously designed studies are needed to support use of heparin as an anti-inflammatory agent in clinical setting. However, because of the association between inflammation, atherogenesis, thrombogenesis, and cell proliferation, heparin and related compounds with pleiotropic effects may have greater therapeutic efficacy than compounds acting against a single target.

## 1. Introduction

Heparin is a highly sulfated glycosaminoglycan (GAG) that is found in the mast cells of most mammals. The endogenous GAGs are highly acidic and actively charged. Heparin is the most sulfated, and acidic GAGs enable it to bind to different component such as coagulating and fibrinolytic proteins, many growth factors, and immune response proteins such as cytokines and chemokines [1, 2]. Heparin is mostly known for its anticoagulant properties, so commercially form of heparin including unfractionated heparin (UFH) and low molecular weight heparin (LMWH) used currently in treatment and prevention of thrombotic events like deep vein thrombosis, pulmonary emboli, acute coronary syndromes, and ischemic

cerebrovascular events as well as prevention of thrombosis in extracorporeal circuits and hemodialysis [3, 4]. Apart from its anticoagulant effects, there are several studies which have shown that heparin possesses various anti-inflammatory and immunomodulatory properties and the mechanisms of anti-inflammatory actions of heparin have been discussed recently [5, 6]. But the exact benefit and safety of heparin and its derivatives as anti-inflammatory agents in clinical setting have not definitely proved yet. Our objective was to systematically review and summarize the literature supporting anti-inflammatory role of heparin to provide evidence about the clinical effectiveness and safety of heparin in inflammatory conditions.

## 2. Methods

**2.1. Search Strategy.** A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, Ovid, Elsevier, and Google Scholar from inception to March 2012 using the following Mesh keywords: (1) heparin, (2) UFH, (3) anticoagulants, (4) dalteparin, (5) enoxaparin, (6) nadroparin, (7) tinzaparin, (8) heparinoids, (9) inflammation, (10) inflammatory process, (11) anti-inflammation, (12) inflammation mediators, (13) inflammatory bowel disease, and (14) anti-inflammatory agents. All keywords from 1 to 8 were separately combined with each keyword from 9 to 14 in all databases. Articles were initially scanned based on titles and abstracts by two reviewers (Sarah Mousavi and Mandana Moradi) and related articles were retrieved in full and assessed for eligibility by two reviewers (Sarah Mousavi and Mandana Moradi). The reference list of each eligible study was checked to identify additional studies.

**2.2. Inclusion Criteria.** All Randomized Clinical Trials (RCTs) and studies with quasi-experimental design which evaluated efficacy, using inflammatory biomarkers levels, and safety (significant hemorrhage or thrombocytopenia) of anti-inflammatory effects of heparin and heparin-related derivatives (LMWH or other heparinoids) with an English abstract regardless of route of administration (intravenous, subcutaneous, topical, or inhaler), age, gender, race, and ethnic origin of participants were included.

**2.3. Exclusion Criteria.** The following were excluded: studies based on animal models; preclinical and biological studies, letters, and editorials; report published as meeting abstract only; where insufficient data were reported to allow inclusion.

**2.4. Data Extraction and Quality Assessment.** Data from each eligible study were extracted individually and compared by two authors (Sarah Mousavi and Mandana Moradi) using standard form that included study design, setting, sample size, duration and follow up, dosing regimen, intervention type, and outcomes. Disagreements were resolved through discussion; if necessary they consulted a third person. A narrative synthesis was conducted.

Quality assessment of clinical trials included in the analysis were performed utilizing the Jadad score, a previously validated instrument that assesses trials based on appropriate randomization, blinding, and description of study withdrawals or dropouts [7]. The description of this score is as follows: (1) whether it is randomized (yes = 1 point, no = 0); (2) whether randomization was described appropriately (yes = 1 point, no = 0); (3) whether it is double-blind (yes = 1 point, no = 0); (4) whether the double-blinding was described appropriately (yes = 1 point, no = 0); (5) whether withdrawals and dropouts were described (yes = 1 point, no = 0). The quality score ranges from 0 to 5 points; a low-quality report score is  $\leq 2$ ; and a high-quality report score is at least 3.

The Consolidated Standards of Reporting Trials (CONSORT) checklist was also used for randomized trials as it is




FIGURE 1: Flow diagram of literature search process.

strongly endorsed by prominent journals and leading editorial organizations [8]. Total possible score for CONSORT checklist was considered as 74: two points for adequate description, one point for inadequate description, and zero for no description.

**2.5. Statistical Methods.** To summarize and extract data, the database was designed by Microsoft office Access 2007 (Microsoft Corporation, Redmond, WA). A narrative synthesis was conducted and data were extracted into tables and summarized.

## 3. Results

Following Initial screening of mentioned databases total of 553 citations (275 duplicates) were extracted but only 70 of them were potentially eligible for investigation of our objectives (according to our proposed inclusion criteria) based on titles and abstracts. The full text screening excluded other 13 citations and the remaining 57 papers were considered relevant for data extraction and following analysis. The flow chart of studies' selection processes is as shown in Figure 1.

**3.1. Study and Patient Characteristic.** Sample sizes ranged from 8 to 555 patients in 57 studies that met the criteria to be included. Research designs mostly were randomized controlled trial ( $n = 48$ ) and the remaining ( $n = 9$ ) had quasi-experimental designs using pre-post studies ( $n = 6$ ).

Tables 1 and 2 [9–62] list the characteristics of the included studies. The most studied clinical conditions was cardiopulmonary bypass ( $n = 12$ ), followed by Asthma ( $n = 8$ ), inflammatory bowel disease (IBD) ( $n = 5$ ), acute coronary syndrome (ACS) ( $n = 8$ ), and ophthalmological disease ( $n = 8$ ). Other less common studied conditions were as follows: burn, cystic fibrosis, allergic rhinitis, superficial

TABLE 1: Summary and findings of common studied diseases.

Clinical setting	Heparin preparation	Mode of administration	Comparator	Number of patients	Clinical outcome	Laboratory outcome	Study design
Exercise-induced Asthma [9]	UFH	Inhaler	Cromolyn sodium or placebo	12	Significantly reduction of exercise-induced asthma	Heparin had no effect on histamine-induced bronchoconstriction	Single-blind, randomized, crossover clinical trial
Asthma [10]	UFH	Inhaler	Placebo	8	Significant reduction of late asthmatic response after allergen administration ( $P: 0.005$ )	—	Randomized, double-blind, crossover clinical trial
Atopic asthma [11]	Heparin (IVX-0142)	Nebulizer	Placebo	19	No significant decrease in early ( $P: 0.06$ ) and late ( $P: 0.24$ ) asthmatic response	—	Randomized single-blind, placebo-controlled, crossover trial
Asthma [12]	LMWH	Nebulizer	—	24	Effective as an add-on therapy to standard treatment	Reduction in eosinophil ( $P: 0.0006$ ) and lymphocyte ( $P: 0.049$ ) in bronchoalveolar lavage. No changes in IL-5 or ECP concentrations in serum	Quasi-experimental (pretest-posttest design)
Allergic asthma [13]	UFH	Inhaler	Placebo	25	Heparin inhalation significantly reduced bronchial hyperreactivity ( $P < 0.05$ )	—	Randomized, double-blind, placebo-controlled, crossover trial
Asthma [14]	UFH	Inhaler	—	12	Transient (time-dependent) inhibitory role in allergic reactions	Increased the methacholine PC20 value ( $P: 0.05$ ) but did not prevent an increase in Raw and/or a decrease in SGAW	Randomized, double-blind, placebo-controlled, crossover trial
Asthma (children) [15]	UFH	Inhaler	Placebo	14	Single dose of heparin significantly ( $P: 0.005$ ) reduced bronchial hyperreactivity	Provocation test used leukotriene D4	Randomized, double-blind, placebo-controlled, crossover trial
Asthma [16]	UFH	Inhaler	Placebo	23	Significant reduction of bronchial hyperreactivity to histamine and leukotriene	—	Randomized, double-blind, placebo controlled, crossover trial
IBD [17]	UFH	IV/SC	Hydrocortisone + prednisolone	20 (12 in control group)	Clinical activity index, stool frequency, and endoscopic and histopathological grading were similar in both treatment groups	CRP and $\alpha 1$ acid glycoprotein did not change	Open label randomized, crossover clinical trial

TABLE I: Continued.

Clinical setting	Heparin preparation	Mode of administration	Comparator	Number of patients	Clinical outcome	Laboratory outcome	Study design
IBD [18]	UFH	SC	—	17	Histology improved significantly in ulcerative colitis patients (UFH is effective in ulcerative colitis but not Crohn disease)	CRP ( $P: 0.0119$ ) and ESR ( $P: 0.0096$ ) significantly reduced in ulcerative colitis but not Crohn disease	Quasi-experimental (pretest-posttest design)
IBD [19]	UFH	IV	Methyl prednisolone	25 (13 in control group)	No effect of heparin, also increased bleeding	No change in CRP	Randomized, double-blind, parallel-group trial
IBD [20]	Enoxaparin + standard treatment	SC	Aminosalicylate + corticosteroid	34 (18 in control group)	Significant improvement in disease severity in both groups ( $P: 0.001$ )	No difference ESR, CRP and fibrinogen and coagulation	Randomized controlled trial
IBD [21]	Nadroparin	SC	—	25	Endoscopic and histological sign of inflammation significantly improved	—	Quasi-experimental (Non-randomized clinical trial)
Cataract surgery [22]	UFH	Intraocular lens (IOL)	Polymethylmethacrylate	524	—	Heparin surface modification reduced the cellular deposit compared to control group	Randomized, double-blind, parallel group clinical trial
Cataract surgery [23]	UFH	Intraocular lens (IOL)	Polymethylmethacrylate	58 (31 in control group)	Postoperative inflammation decreased significantly in heparin group ( $P: 0.02$ )	Giant cell and cell deposit decreased significantly ( $P < 0.05$ )	Randomized, double-blind, clinical trial
Cataract surgery (pediatric) [24]	UFH	Irrigation	Balanced salt solution	33 (19 in control group)	Heparin irrigation reduced number of postoperative inflammatory related complication	Anterior chamber reaction including fibrin formation was lower in heparin group	Randomized prospective double-blind trial
Cataract surgery (pediatrics) [25]	Enoxaparin	Irrigation	No treatment	40 (20 in each group)	Increase of flare and cell deposit after surgery (1 and 3 months) ( $P: 0.99$ )	Increase in large cell deposits	Randomized, double-blind, controlled trial
Cataract surgery [26]	UFH	Irrigation	Regular irrigation solution	72	Significant reduction of inflammation in the early period (days 1–3) postoperative ( $P < 0.01$ )	—	Randomized controlled trial
Cardiopulmonary bypass (pediatric) [27]	Heparin-coated circuit ( $n = 11$ )	—	Non-heparin-coated circuit ( $n = 10$ )	21	Decrease of systemic inflammatory response with the use of heparin-bonded oxygenators	Significantly decreased levels of IL-6, IL-8, terminal complement complex, neutrophils, and elastase in heparin coated circuit	Randomized controlled trial
Cardiopulmonary bypass [28]	Heparin-coated circuit $\pm$ aprotinin	—	Uncoated circuit $\pm$ aprotinin	200 (4 groups)	Aprotinin and heparin had no effect on cytokine release	TNF- $\alpha$ , IL-6, and IL-8 and myeloperoxidase did not change	Randomized, double-blind, clinical trial

TABLE I: Continued.

Clinical setting	Heparin preparation	Mode of administration	Comparator	Number of patients	Clinical outcome	Laboratory outcome	Study design
Cardiopulmonary bypass [29]	UFH	—	Uncoated circuit	51 (26 in each group)	Decreased pulmonary vascular resistance index and pulmonary shunt fraction, and increased PaO <sub>2</sub> /FIO <sub>2</sub> ratio	Lower levels of phospholipase A2 and complement activation ( $P < 0.001$ )	Randomized, double-blind, clinical trial
Cardiopulmonary bypass [30]	Heparin-coated circuit	—	Non-heparin-coated circuit	16 (9 in control group)	—	No significant difference between groups regarding: granulocyte elastase IL-6, IL-8	Quasi-experimental (pretest-posttest design)
Cardiopulmonary bypass [31]	Heparin concentration-based system	—	Activated clotting time-based management	200 (100 in control group)	No effect on postoperative blood loss	Significant reduction of neutrophil activation and fibrinolysis and thrombin generation ( $P < 0.05$ )	Randomized controlled trial
Cardiopulmonary bypass (pediatric) [32]	Heparin-coated circuit	—	Non-heparin-coated circuit	19 (10 in control group)	Improvement of the biocompatibility of CPB during heart surgery	Levels of complement factor C3a ( $P < 0.001$ ) and IL-6 ( $P < 0.005$ ) significantly reduced in heparin-coated circuit	Randomized controlled trial
Cardiopulmonary bypass (pediatric) [33]	Heparin-coated circuit	—	Non-heparin-coated circuit	34 (12 in control group)	No differences in duration of intubation, intensive care unit or hospital stay, or postoperative blood loss	IL-6, IL-8, and TNF- $\alpha$ were significantly lower in heparin group ( $P < 0.01$ , $P < 0.01$ , and $P < 0.05$ , resp.)	Randomized controlled trial
Cardiopulmonary bypass [34]	Heparin-coated circuit (heparin + aprotinin)	—	Non-heparin-coated circuit (heparin + aprotinin)	30 (15 in each group)	No significant differences between the two groups in terms of bleeding and transfusional requirements, the time spent on a ventilator, or in duration of stay in the intensive care unit (ICU)	Levels of IL-6, CRP, and neutrophil count did not change by heparin-coated circuit. Monocyte count increased in heparin-coated circuit	Randomized controlled trial
Coronary artery bypass grafting (CABG) [35]	Heparin-coated circuit	—	Non-heparin-coated circuit	18 (9 in each group)	—	Reduction of levels of IL-8 and TNF- $\alpha$ and increase of neutrophil elastase	Randomized controlled trial

CRP: C-Reactive Protein, CPB: Cardio Pulmonary Bypass, ECP: Eosinophil Cationic Protein, ESR: Erythrocyte Sedimentation, ICU: Intensive Care Unit, IL: interleukin, IV: intravenous, SC: subcutaneous, SGAW: Specific Airway Conductance, TNF: Tumor Necrosis Factor, and UFH: unfractionated heparin.

TABLE 2: Summary and findings of other studied diseases.

Clinical setting	Heparin preparation	Mode of administration	Comparator	Number of patients	Clinical outcome	Laboratory outcome	Study design
Pancreatitis after ERCP [36]	UFH	SC	Saline solution	105 (54 in control group)	Rate of postoperative pancreatitis was not significant between both groups	—	Randomized placebo-controlled clinical trial
Acute coronary syndrome (ACS) [37]	UFH	SC	Enoxaparin	201	—	No significant difference between CD4 ligand and PAI-1 in both groups	Open label, randomized, clinical trial
Skin or pulmonary allergy [38]	UFH	IV/nebulizer	Normal saline/placebo	25	Significant inhibition of mast cell-mediated allergic inflammation ( $P: 0.04$ )	—	Double-blind, placebo-controlled, crossover clinical trial
COPD [39]	UFH	IV	—	37 (18 in control group)	Significant improvement in bronchospasm and bronchial secretions (58% response rate)	—	Randomized placebo-controlled clinical trial
COPD [40]	Nadroparin	SC	Conventional treatment	66 (33 in each group)	Decrease of duration of mechanical ventilation and length of hospital and ICU stay ( $P < 0.01$ )	Significant decrease in levels of CRP, IL-6, and fibrinogen	Randomized controlled trial
Ischemic stroke [41]	UFH	IV	Aspirin	167 (97 in control group)	Early onset initiation of heparin might improve recovery after stroke	Rise of sVCAM-1 at 48h was significantly lower in patients treated with UFH ( $P < 0.01$ )	Quasi-experimental (controlled observational study)
Ligneous conjunctivitis [42]	UFH	Topical	Alpha chymotrypsin or steroid	17 (12 in control group)	Intensive and early use of topical heparin may improve therapy results in disease	—	Quasi-experimental (nonrandomized Clinical trial)
Endotoxemia (induced by lipopolysaccharide in healthy subjects) [43]	UFH	IV	LMWH or placebo	30 (10 in each group)	—	No effect on TNF- $\alpha$ , IL-6 and 8, CRP, and E-selectin	Randomized, double-blinded, placebo-controlled parallel group trial
Mechanical ventilation [44]	UFH	Nebulizer	Normal saline (placebo)	50 (25 in each group)	Fewer days on mechanical ventilation, better Pao2/Fio2 ratio	—	Double-blind, randomized, placebo-controlled trial
Percutaneous coronary intervention [45]	Bivalirudin	IV	UFH + eptifibatide	63 (29 in control group)	—	Increase in IL-6 and CRP after 1 day. Decrease in CRP in bivalirudin group after 30 days ( $P: 0.002$ )	Randomized controlled trial
Cystic fibrosis (adults) [46]	UFH	Inhaler	—	12 (6 in control group)	Spirometry parameters did not change	IL-6 reduced after treatment	Quasi-experimental (pretest-posttest design)

TABLE 2: Continued.

Clinical setting	Heparin preparation	Mode of administration	Comparator	Number of patients	Clinical outcome	Laboratory outcome	Study design
Cystic fibrosis (adults) [47]	UFH	Inhaler	Placebo	14	No effect on FEV1	No effect on sputum inflammatory markers	Randomized, double-blind, placebo-controlled crossover trial
Hemodialysis patients [48]	UFH	IV/SC	LMWH and no drug	33	LMWH decreased oxidative stress and inflammation whereas heparin increased them	CRP, TNF- $\alpha$ , superoxide dismutase, MDA increased in heparin group but comparable to LMWH group	Quasi-experimental (pretest-posttest design)
Stable angina [49]	Heparin + Aspirin (n = 15)	—	Argatroban + Aspirin (n = 12) 27		No difference in inflammatory response after angioplasty	Fibrinogen decreased significantly in argatroban group. No difference in von Willbrand factor between both groups. PAI-1 increased in argatroban group	Randomized controlled trial
Phacoemulsification [50]	Heparin	Coated lenses	Polymethylmethacrylate lenses	367	Heparin coated lenses reduced significantly inflammation early postoperation (P: 0.05)		Randomized, double-blind, multicenter, parallel group trial
Allergic rhinitis [51]	UFH	Intranasal	—	10	—	Reduction of eosinophil cationic protein in the nasal wash	Quasi-experimental (pretest-posttest design)
Phacomorphic glaucoma [52]	Dalteparin	Irrigation	Balanced salt solution	46 (23 in each group)	Significant decrease of postoperative inflammation in dalteparin group	—	Randomized, double-blind, clinical trial
Burn [53]	Dalteparin	SC	No treatment	24	—	Decrease of nitric oxide synthetase activity significantly	Quasi-experimental (nonrandomized clinical trial)
Unstable coronary artery disease [54]	Enoxaparin (n = 46) Dalteparin (n = 48)	SC	UFH (n = 47)	68	Von Willbrand factor may have prognostic value, but other biological variables did not predict outcome	CRP, fibrinogen, Von Willbrand factor increased over first 2 days despite medical treatment. Enoxaparin (13%) and dalteparin (19%) reduced release of Von Willbrand factor	Open label, randomized, clinical trial
ST-Elevated Myocardial Infarction (STEMI) [55]	Enoxaparin	SC	UFH	34 (17 in each group)	Both heparin and enoxaparin show anti-inflammatory effects in STEMI patients	Serum Amyloid A (P:0.02), CRP (P: 0.02), and ferritin (P: 0.01) reduced in heparin group. IL-6 (P: 0.002), SAA (P: 0.009), CRP (P: 0.01) were significantly decreased in enoxaparin group. The overall difference between groups was not significant	Open label, randomized, clinical trial

TABLE 2: Continued.

Clinical setting	Heparin preparation	Mode of administration	Comparator	Number of patients	Clinical outcome	Laboratory outcome	Study design
Coronary artery disease [56]	Dalteparin	SC	Placebo	555 (285 in control group)	Dalteparin reduced coagulation and so Myocardial Infarction but has not inflammatory activity	No effects on IL-6, C-reactive protein and fibrinogen	Randomized, double-blind, parallel-group, multicentre trial
Stable coronary artery disease [57]	Enoxaparin	SC	Sodium chloride	62 (31 in each group)	By mobilizing vessel bound MPO, enoxaparin improves endothelial function	Significant increase of MPO levels	Randomized, double-blind, placebo-controlled trial
Acute coronary syndrome and PCI [58]	Tirofiban (high dose) + enoxaparin	SC	Tirofiban (high dose) + UFH	60 (30 in each group)	The combination of tirofiban (high dose) + enoxaparin reduced inflammation after PCI	Von willberand, CRP, D-dimer, and prothrombin fragment were significantly lower in enoxaparin group than UFH	Open label randomized controlled trial
Superficial venous thrombophlebitis [59]	Dalteparin	SC	Ibuprofen	72 (37 in dalteparin group)	Significant reduction of pain form baseline to day 14 of follow-up. No difference on thrombosis progression after 3 months	—	Randomized, double-blind, controlled trial
Superficial venous thrombosis [60]	Nadroparin	SC	Naproxen	117 (39 in control group)	Nadroparin reduced symptom and signs of thrombosed superficial vein better than naproxen ( $P: 0.007$ )	—	Randomized, open label clinical trial
Superficial venous thrombosis [61]	Nadroparin	SC	Nadroparin + acemetacin	50	Significant symptom improvement in both groups ( $P: 0.001$ ). The combination group was better	—	Randomized controlled trial
Peritoneal dialysis patients [62]	Tinzaparin	Intraperitoneal	Isotonic saline	21	Reduction of local and systemic inflammation in peritoneal dialysis patients	Reduced levels of CRP ( $P: 0.032$ ) and fibrinogen ( $P: 0.042$ ) and IL-6 ( $P: 0.007$ ) in dialysate.	Randomized, double-blind, placebo-controlled crossover trial

COPD: Chronic Obstructive Pulmonary Disease, CRP: C-Reactive Protein, CPB: Cardio Pulmonary Bypass, ECP: Eosinophil Cationic Protein, ERCP: Endoscopic Retrograde Cholangiopancreatography, ESR: Erythrocyte Sedimentation, ICU: Intensive Care Unit, IL: interleukin, IV: intravenous, LMWH: low molecular weight heparin, MDA: malondialdehyde, PAI: Plasminogen Activator Inhibitor, SC: subcutaneous, sVCAM: Soluble Vascular Cell Adhesion Molecule, TNF: Tumor Necrosis Factor, and UFH: unfractionated heparin.

TABLE 3: Summary of numbers and percentages of adequately reported items in each trial according to CONSORT checklist and Jadad score.

Trials	Jadad score	Adequately reported items ( $n/N$ )	Percentage (%)
Abdollahi et al. [52]	4	29/74	39.2%
Ahmed et al. [9]	3	20/74	27%
Ang et al. [17]	2	24/74	32.4%
Ashraf et al. [27]	2	22/74	29.7%
Becker et al. [37]	3	28/74	37.8%
de Vroege et al. [29]	3	26/74	35.1%
Defraigne et al. [28]	4	28/74	37.8%
Derhaschnig et al. [43]	3	32/74	43.2%
Dixon et al. [44]	4	50/74	67.5%
Duong et al. [11]	3	30/74	40.5%
Gu et al. [71]	2	16/74	21.6%
Jerzynska et al. [13]	3	20/74	27%
Keating et al. [45]	2	21/74	28.4%
Koster et al. [31]	2	26/74	35.1%
Montalescot et al. [54]	3	35/74	47.3%
Nasiripour et al. [55]	2	34/74	46%
Oldgren et al. [56]	3	27/74	36.5%
Olsson et al. [32]	2	25/74	33.8%
van Ophoven et al. [79]	2	27/74	36.5%
Ozawa et al. [33]	2	27/74	36.5%
Özkurt et al. [24]	3	18/74	24.3%
Paparella et al. [72]	2	22/74	29.7%
Polosa et al. [67]	3	23/74	31.1%
Rathbun et al. [59]	5	44/74	59.5%
Rudolph et al. [57]	3	31/74	41.2%
Serisier et al. [47]	5	45/74	60.8%
Stelmach et al. [16]	3	31/74	41.2%
Suzuki et al. [49]	2	23/74	31%
Vancheri et al. [51]	4	22/74	29.7%
Vasavada et al. [25]	5	52/74	70.2%
Walters et al. [58]	3	32/74	43.2%
Zezos et al. [20]	3	37/74	50%

thrombophlebitis, and hemodialysis. Unfractionated heparin (UFH) was used in forty studies as subcutaneous, intravenous, inhaler, or heparin-coated circuits while others used enoxaparin ( $n = 3$ ), dalteparin ( $n = 4$ ), nadroparin ( $n = 4$ ), and tinzaparin ( $n = 1$ ).

Table 3 provides information on the adequately reported items according to Jadad score and CONSORT items. Among these 32 papers, 11 (35.4%) scored 2 and the remaining studies scored 3 or higher according to Jadad score and just three studies fulfill the criteria of Jadad score. Calculated quality scores according to CONSORT checklist range from 21% to 70% in our object studies with twelve studies scoring greater than 40%. The following characteristics were not exactly reported in more than half of the trials: identification as

a randomized trial in the title, information about the setting and location of studies, determination of sample size, allocation and implementation of randomization, participant flow, recruitment and follow-up, subgroup analysis, limitations of study, harms, registration number, access to full trial protocol, and funding source.

## 4. Discussion

We discuss evidence from clinical studies supporting an anti-inflammatory role for heparin and heparin-related derivatives.

**4.1. Asthma.** Asthma is a chronic inflammatory disorder of airways characterized by bronchial hyperresponsiveness resulting in episodic bronchospasm. Several studies in 1960s described subjective improvement of symptoms in asthmatic patients using intravenous heparin for the first time [39, 63]. Inhaled heparin or its derivatives have been shown to possess antiasthmatic properties in various clinical models: allergen induced [38, 64], exercise [9], adenosine [6], and distilled water challenge models [65]. Seven randomized controlled crossover trials studied anti-inflammatory effects of heparin in exercise-induced or allergen-induced asthma having sample size range from 8 to 25 in 5 trials.

Heparin inhalation reduced bronchial hyperreactivity in a single-blind randomized crossover trial ( $n = 12$ ) by Ahmed et al. [9]. Heparin inhalation (1000  $\mu$ /kg) prevents exercise-induced asthma ( $P < 0.05$ ) without prevention of histamine-induced bronchoconstriction. Stelmach et al. [66] provoke challenge tests with histamine or leukotriene D4 before and after inhalation of heparin; showed that heparin (5000 Iu) decreases histamine and leukotriene-induced bronchial hyperreactivity compared to placebo significantly ( $P: 0.043$  and  $0.005$ ) but changes in Forced Expiratory Volume (FEV 1) were not significant ( $P: 0.064$ ). The inhibitory effects of inhaled heparin in the airways in the absence of bronchodilation might be related to suppressive action on mast cell degranulation. A randomized, double-blind study in 10 subjects with asthma showed that heparin inhalation attenuates airway response to adenosine 5'-monophosphate (AMP) but not to methacholine ( $P < 0.01$ ) suggesting the theory that heparin acts more likely in association to modulation of mediator release compared to a direct effect on smooth muscle [67].

Our results showed that inhaled enoxaparin was used just in a pre-post study of 24 asthmatic patients, measuring inflammatory biomarkers, and showed a reduction in eosinophil ( $P: 0.006$ ) and lymphocytes of bronchoalveolar lavage without any significant change in IL-5 or Eosinophil Cationic Protein (ECP) concentrations [12]. Therefore, it seems that enoxaparin could be a valuable add on treatment in asthma like UFH. Duong et al. [11] evaluated IVX-0142 nebulizer, a heparin-derived hypersulfated disaccharide, in asthma and showed nonsignificant decrease in early and late asthmatic response.

Performed studies did not show any adverse events or harms with heparin or related compounds except increase in

the plasma partial thromboplastin time reported by Ahmed et al. [9].

All in one, considering the results of these studies, we can conclude that heparin and its derivatives could have anti-inflammatory effects and could be considered along with other treatments in asthma.

**4.2. Cardiopulmonary Bypass.** Contact and interaction of blood with foreign surfaces during cardiopulmonary bypass (CPB) cause systemic inflammatory response syndrome (SIRS) through activation of several humoral cascades including cytokines such as IL-6, IL-8, and Tumor Necrosis Factor- $\alpha$  (TNF- $\alpha$ ) [68]. The inflammatory response can be attenuated by promoting the biocompatibility of the CPB circuit. Use of heparin-treated surfaces in CPB circuits has been shown to decrease activation of leukocytes and the complement cascades [5]. As a result, need to inotropic support, postoperative time of mechanical ventilation, and rate of acute lung injury decrease and patients duration of hospital stay shortens, which reflects the positive effect of heparin in CPB circuits [69, 70]. Twelve studies whose endpoints were the effects of heparin-bonded circuits on inflammatory markers were included in our analysis and in the majority of these trials [27, 29, 32–35, 71]; heparin-coated circuit significantly decreased the level of cytokines such as IL-6, IL-8, TNF- $\alpha$ , complement complex, neutrophils, and elastase compared to non-heparin-coated circuit.

Defraigne et al. [28] randomized 200 patients in 4 groups; heparin-coated circuit with or without aprotinin administration and uncoated circuit with or without aprotinin administration. They measured IL-6, IL-8, TNF- $\alpha$ , myeloperoxidase (MPO), and elastase level and concluded that cytokine release and neutrophil activation were not attenuated by heparin-coated circuit or by the administration of aprotinin. Misawa et al. [30] evaluated cytokines level under normothermic CPB, in a small observational controlled study ( $n = 19$ , 9 in control group). Levels of IL-6, IL-8, and ICAM-1 (indicator of endothelial damage) were not different between study and control group. However, as mentioned before, most studies indicate the favorable effect of heparin-coated circuit on inflammatory responses in CPB.

Paparella et al. [72] compared two doses of heparin and 300 Iu/kg and 600 Iu/kg in 40 patients undergoing CPB in an RCT and showed that IL-6 and TNF- $\alpha$  plasma levels were in association to heparin dose. It seems that lower heparin dose had small influence on proinflammatory cytokines release; however, higher doses make a better regulatory effect on coagulation system.

The side effects of heparin-coated circuits were not reported. In these studies, just a number of included studies reported a decrease in platelet levels in both groups (coated and noncoated circuit). No major events including hemorrhage were reported.

**4.3. Inflammatory Bowel Diseases (IBD).** Hypercoagulable state may be an important contributing factor in the pathogenesis of IBD, especially ulcerative colitis (UC) [73]. A number of studies evaluate the effects of heparin administration on UC but the results obtained are controversial [17, 19].

Bloom et al. [74] did not find any favorable effect of LMWH, tinzaparin, over placebo in the treatment of active UC in a double-blind randomized, placebo controlled, multicenter trial ( $n = 100$ ) evaluating mean change in colitis activity as the primary endpoint. Ang et al. [17] compared heparin to hydrocortisone plus prednisolone in 20 patients (UC,  $n = 17$ , Crohn's colitis,  $n = 3$ ) in open-label randomized crossover trial which measured endpoints; clinical disease activity, stool frequency and  $\alpha_1$  acid glycoprotein, and endoscopic and histopathological grading indicate the efficacy and safety of heparin compared to corticosteroids ( $P > 0.05$ ); in contrast the study by Panes et al. [19] did not show the efficacy of heparin in UC compared to methylprednisolone.

Zezos et al. [20] compared enoxaparin with standard treatment (aminosalicylate + corticosteroids) in 34 patients with active UC. The inflammatory biomarkers including C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), and fibrinogen did not show any difference in study group compared to control and both groups showed similar rate of disease improvement ( $P > 0.05$ ); furthermore, coagulation factors did not change from one to another. Authors concluded that enoxaparin is a safe adjuvant but has no additive benefit over standard treatment of UC.

Generally the studies show conflicting results. The heparin and LMWHs showed efficacy in regard of disease activity and also well tolerated but inflammatory markers did not change significantly. Therefore the improvement in disease activity might be the result of heparin's anticoagulant effects.

**4.4. Acute Coronary Syndrome (ACS).** Inflammation has a key role in the pathogenesis of coronary artery plaque destabilization and rupture leading to acute coronary syndromes (ACS) [75]. Leukocyte activation, monocyte, and neutrophil infiltration result in local and systemic inflammatory responses [76]. Heparin and LMWHs are commonly used in ACS to prevent clot formation; they also seem to have desirable effects on inflammatory markers level based on sparse data.

We found 8 studies about heparin and LMWHs in CADs evaluating anti-inflammatory effects as their endpoints. Oldgren et al. [56] found that dalteparin administration in patients with unstable CAD ( $n = 555$ ) did not affect IL-6, C-Reactive Protein (CRP), and fibrinogen levels, although it reduced coagulation activity and mortality rate in long term, so it is concluded that these effects are not related to its anti-inflammatory properties. Walters et al. [58] compared high dose of tirofiban/enoxaparin ( $n = 30$ ) with tirofiban/heparin ( $n = 30$ ) in an open-label randomized controlled trial in high risk percutaneous intervention. They found that combination of high dose of tirofiban with enoxaparin significantly attenuate inflammatory process (decreased levels of CRP, and von Willebrand factor) compared to tirofiban and heparin.

The ARMADA study [54] evaluated anti-inflammatory effects of heparin and enoxaparin in Non-ST-Elevated Myocardial Infarction (Non-STEMI) and reported that inflammatory markers (CRP and von Willebrand factor) are affected more by LMWH compared to UFH. However because of the small sample size of the study ( $n = 68$ )

it did not acquire sufficient statistical power to prove any effects on defined outcomes. Nasiripour et al. [55] found that both enoxaparin and heparin reduce inflammatory markers in STEMI patients at the same level; however, this study had the same limitations of sample size ( $n = 34$ ) and power too.

In summary considering heparins as the main stay treatment of ACS, its effects are more pronounced as anticoagulating than as an anti-inflammatory agent in this pathological condition.

**4.5. Cataract Surgery.** Postoperative inflammation is observed in cataract surgery especially in children. Newer techniques as lensectomy and phacoemulsification cause less complication but still pose potential risks [77, 78]. It has been suggested that a heparin surface-modified intraocular lens (IOL) or augmenting the irrigating solution with heparin during cataract surgery may reduce the incidence of postoperative inflammation. Borgioli et al. [22] confirm this hypothesis that heparin surface-modified IOL will reduce the inflammatory response compared to conventional IOL at least in short term period (3 months) in a large (524 patients) double-blind, multicenter trial. A similar study by Colin et al. [23] ( $n = 58$ ) confirms their results; however, the power of Borgioli et al. study was higher. Heparinized lenses showed also more anti-inflammatory effects during long term follow-up (1 year). Heparinized irrigating solution was used during cataract surgery in two different studies and inflammation decrease observed in the early postoperative period of both studies (Kohnen et al. [26] and Özkurt et al. [24]). Therefore, it seems that heparin in both forms have anti-inflammatory effects in cataract surgery.

Vasavada et al. [25] used enoxaparin irrigation solution in 20 children undergoing bilateral cataract surgery but they did not find any beneficial effect in early postoperative inflammation. This study acquired the highest quality in the study quality assessment process, based on Jadad score and CONSORT items (52/74, 70.2%). It is worth noticing that the majority of items mentioned in the CONSORT checklist were adequately reported and covered in this paper.

Potential mechanisms of anti-inflammatory effects of heparin have been discussed completely in a review by Young [6]. Binding of heparin to different mediators involved in the immune system response (cytokines and chemokines), acute phase proteins, and complement complex proteins may contribute to the anti-inflammatory activity of heparin. Neutralizing of cytokines at the inflammation site is another possible mechanism. In most of the studies level of cytokines such as IL-6, IL-8, TNF- $\alpha$ , and CRP was decreased after heparin administration, which can confirm this mechanism; also heparin and LMWHs inhibit adhesion of leukocytes and neutrophils to endothelial cells by binding to p-selectin, and consequently prevent release of oxygen radicals and proteolytic enzymes. Other possible mechanisms are as follows: inhibition of nuclear factor  $\kappa$ B (NF- $\kappa$ B) and induction of apoptosis by modulation of activity of TNF- $\alpha$  and NF- $\kappa$ B. In a double-blind placebo-controlled trial ( $n = 62$ ) in patients with stable coronary artery disease, following administration of 1 mg/kg subcutaneous enoxaparin, plasma levels of myeloperoxidase (MPO) increased significantly

( $P < 0.001$ ) and subsequently endothelial function improved ( $r = 0.67$ ,  $P < 0.001$ ) through MPO binding to endothelium and depleting vascular nitric oxide [57]. This study confirms another possible mechanism of heparins anti-inflammatory effects.

## 5. Conclusion

As we discussed heparins potential effects as anti-inflammatory agents, supported by several clinical trials in various setting. Heparin and its related derivatives have been shown to benefit patients with asthma and patients undergoing cardiopulmonary bypass and cataract surgery. In other inflammatory diseases, such as IBD (ulcerative colitis), the studies are heterogeneous and incongruent. Most studies did not report any unwanted event with heparins when they used them as anti-inflammatory agents whether through systemic or through local (as inhaler or irrigation or heparin-coated circuit) administration. However, because the majority of these trials did not pose optimal quality scores, we cannot draw a definite conclusion on the efficacy of heparin and its derivatives as anti-inflammatory agents.

The present review included studies which measured inflammatory markers as their endpoints and in most of them these markers were decreased though not significantly. To come to a definite conclusion further double-blind, randomized, placebo-controlled clinical trials with a larger sample size are needed. However, because the inflammation, atherogenesis, thrombogenesis, and cell proliferation are associated with each other, the pleiotropic effects of heparin and related compounds may have greater therapeutic effect than compounds that are directed against a single target.

## Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

## References

- [1] B. Casu, "Heparin structure," *Pathophysiology of Haemostasis and Thrombosis*, vol. 20, supplement 1, pp. 62–73, 1990.
- [2] J. Hirsh, R. Raschke, T. E. Warkentin, J. E. Dalen, D. Deykin, and L. Poller, "Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety," *Chest*, vol. 108, no. 4, supplement, pp. 258S–275S, 1995.
- [3] J. Fareed, D. A. Hoppensteadt, and R. L. Bick, "An update on heparins at the beginning of the new millennium," *Seminars in Thrombosis and Hemostasis*, vol. 26, no. 3, pp. 5–21, 2000.
- [4] J. Hirsh, "Drug therapy: heparin," *The New England Journal of Medicine*, vol. 324, no. 22, pp. 1565–1574, 1991.
- [5] R. J. Ludwig, "Therapeutic use of heparin beyond anticoagulation," *Current Drug Discovery Technologies*, vol. 6, no. 4, pp. 281–289, 2009.
- [6] E. Young, "The anti-inflammatory effects of heparin and related compounds," *Thrombosis Research*, vol. 122, no. 6, pp. 743–752, 2008.

- [7] A. R. Jadad, R. A. Moore, D. Carroll et al., "Assessing the quality of reports of randomized clinical trials: is blinding necessary?" *Controlled Clinical Trials*, vol. 17, no. 1, pp. 1–12, 1996.
- [8] K. F. Schulz, D. G. Altman, and D. Moher, "CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials," *International Journal of Surgery*, vol. 9, no. 8, pp. 672–677, 2011.
- [9] T. Ahmed, J. Garrigo, and I. Danta, "Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin," *The New England Journal of Medicine*, vol. 329, no. 2, pp. 90–95, 1993.
- [10] Z. Diamant, M. C. Timmers, H. Van Der Veen, C. P. Page, F. J. Van Der Meer, and P. J. Sterk, "Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma," *American Journal of Respiratory and Critical Care Medicine*, vol. 153, no. 6, pp. 1790–1795, 1996.
- [11] M. Duong, D. Cockcroft, L.-P. Boulet et al., "The effect of IVX-0142, a heparin-derived hypersulfated disaccharide, on the allergic airway responses in asthma," *Allergy*, vol. 63, no. 9, pp. 1195–1201, 2008.
- [12] A. M. Fal, M. Kraus-Filarska, J. Miecielica, and J. Malolepszy, "Mechanisms of action of nebulized low-molecular-weight heparin in patients with bronchial asthma," *The Journal of Allergy and Clinical Immunology*, vol. 113, no. 2, supplement, p. S36, 2004.
- [13] J. Jerzynska, I. Stelmach, P. Majak, and P. Kuna, "The effect of inhaled heparin on airway responsiveness to histamine and metacholine in asthmatic children," *Journal of Allergy and Clinical Immunology*, vol. 109, no. 1, supplement 1, p. S39, 2002.
- [14] A. F. Kalpaklioğlu, Y. S. Demirel, S. Saryal, and Z. Misirligil, "Effect of pretreatment with heparin on pulmonary and cutaneous response," *Journal of Asthma*, vol. 34, no. 4, pp. 337–343, 1997.
- [15] I. Stelmach, J. Jerzynska, A. Brzozowska, and P. Kuna, "The effect of inhaled heparin on postleukotriene bronchoconstriction in children with asthma," *Journal of Allergy and Clinical Immunology*, vol. 109, no. 1, supplement 1, p. S39, 2002.
- [16] I. Stelmach, J. Jerzynska, W. Stelmach et al., "The effect of inhaled heparin on airway responsiveness to histamine and leukotriene D<sub>4</sub>," *Allergy and Asthma Proceedings*, vol. 24, no. 1, pp. 59–65, 2003.
- [17] Y. S. Ang, N. Mahmud, B. White et al., "Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease," *Alimentary Pharmacology and Therapeutics*, vol. 14, no. 8, pp. 1015–1022, 2000.
- [18] C. Folwaczny, B. Wiebecke, and K. Loeschke, "Unfractionated heparin in the therapy of patients with highly active inflammatory bowel disease," *The American Journal of Gastroenterology*, vol. 94, no. 6, pp. 1551–1555, 1999.
- [19] J. Panes, M. Esteve, E. Cabre et al., "Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis," *Gastroenterology*, vol. 119, no. 4, pp. 903–908, 2000.
- [20] P. Zazos, G. Papaioannou, N. Nikolaidis et al., "Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study," *Alimentary Pharmacology and Therapeutics*, vol. 23, no. 10, pp. 1443–1453, 2006.
- [21] A. A. Vrij, J. M. Jansen, E. J. Schoon, H. C. Hemker, and R. W. Stockbrügger, "Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi," *Scandinavian Journal of Gastroenterology, Supplement*, vol. 36, no. 234, pp. 41–47, 2001.
- [22] D. M. Borgioli, D. J. Coster, R. F. T. Fan et al., "Effect of heparin surface modification of polymethylmethacrylate intraocular lenses on signs of postoperative inflammation after extracapsular cataract extraction: one-year results of a double-masked multicenter study," *Ophthalmology*, vol. 99, no. 8, pp. 1248–1255, 1992.
- [23] J. Colin, S. Roncin, and M. Wenzel, "Efficacy of heparin surface-modified IOLs in reducing postoperative inflammatory reactions in patients with exfoliation syndrome—a double-blind comparative study," *European Journal of Implant and Refractive Surgery*, vol. 7, no. 5, pp. 266–270, 1995.
- [24] Y. B. Özkurt, A. Taşkıran, N. Erdogan, B. Kandemir, and Ö. K. Doğan, "Effect of heparin in the intraocular irrigating solution on postoperative inflammation in the pediatric cataract surgery," *Clinical Ophthalmology*, vol. 3, no. 1, pp. 363–365, 2009.
- [25] V. A. Vasavada, M. R. Praveen, S. K. Shah, R. H. Trivedi, and A. R. Vasavada, "Anti-inflammatory effect of low-molecular-weight heparin in pediatric cataract surgery: a randomized clinical trial," *The American Journal of Ophthalmology*, vol. 154, no. 2, pp. 252–258, 2012.
- [26] T. Kohonen, B. Dick, V. Hessemer, D. D. Koch, and K. W. Jacobi, "Effect of heparin in irrigating solution on inflammation following small incision cataract surgery," *Journal of Cataract & Refractive Surgery*, vol. 24, no. 2, pp. 237–243, 1998.
- [27] S. Ashraf, Y. Tian, D. Cowan, A. Entress, P. G. Martin, and K. G. Watterson, "Release of proinflammatory cytokines during pediatric cardiopulmonary bypass: heparin-bonded versus nonbonded oxygenators," *Annals of Thoracic Surgery*, vol. 64, no. 6, pp. 1790–1794, 1997.
- [28] J.-O. Defraigne, J. Pincemail, R. Larbuisson, F. Blaffart, and R. Limet, "Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration," *Annals of Thoracic Surgery*, vol. 69, no. 4, pp. 1084–1091, 2000.
- [29] R. de Vroege, W. van Oeveren, J. van Klarenbosch et al., "The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators," *Anesthesia and Analgesia*, vol. 98, no. 6, pp. 1586–1594, 2004.
- [30] Y. Misawa, K. Kawahito, H. Konishi, and K. Fuse, "Cytokine mediated endothelial activation during and after normothermic cardiopulmonary bypass: Heparin-bonded versus non heparin-bonded circuits," *ASAIO Journal*, vol. 46, no. 6, pp. 740–743, 2000.
- [31] A. Koster, T. Fischer, M. Praus et al., "Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management," *Anesthesiology*, vol. 97, no. 4, pp. 837–841, 2002.
- [32] C. Olsson, A. Siegbahn, A. Henze et al., "Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin-6 in paediatric heart surgery," *Scandinavian Cardiovascular Journal*, vol. 34, no. 1, pp. 33–40, 2000.
- [33] T. Ozawa, K. Yoshihara, N. Koyama, Y. Watanabe, N. Shiono, and Y. Takanashi, "Clinical efficacy of heparin-bonded bypass circuits related to cytokine responses in children," *The Annals of Thoracic Surgery*, vol. 69, no. 2, pp. 584–590, 2000.
- [34] A. Parolari, F. Alamanni, T. Gherli et al., "High dose aprotinin and heparin-coated circuits: Clinical efficacy and inflammatory response," *Cardiovascular Surgery*, vol. 7, no. 1, pp. 117–127, 1999.
- [35] H. Yamada, I. Kudoh, Y. Hirose, M. Toyoshima, H. Abe, and K. Kurahashi, "Heparin-coated circuits reduce the formation of

- TNF $\alpha$  during cardiopulmonary bypass,” *Acta Anaesthesiologica Scandinavica*, vol. 40, no. 3, pp. 311–317, 1996.
- [36] O. Barkay, E. Niv, E. Santo, R. Bruck, A. Hallak, and F. M. Konikoff, “Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial,” *Surgical Endoscopy and Other Interventional Techniques*, vol. 22, no. 9, pp. 1971–1976, 2008.
- [37] R. C. Becker, K. W. Mahaffey, H. Yang et al., “Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome,” *Journal of Thrombosis and Thrombolysis*, vol. 31, no. 2, pp. 146–153, 2011.
- [38] S. D. Bowler, S. M. Smith, and P. S. Lavercombe, “Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects,” *American Review of Respiratory Disease*, vol. 147, no. 1, pp. 160–163, 1993.
- [39] J. P. Boyle, R. H. Smart, and J. K. Shirey, “Heparin in the treatment of chronic obstructive bronchopulmonary disease,” *The American Journal of Cardiology*, vol. 14, no. 1, pp. 25–28, 1964.
- [40] Y. Qian, H. Xie, R. Tian, K. Yu, and R. Wang, “Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support,” *COPD: Journal of Chronic Obstructive Pulmonary Disease*, vol. 11, no. 2, pp. 171–176, 2014.
- [41] Á. Chamorro, Á. Cervera, J. Castillo, A. Dávalos, J. J. Aponte, and A. M. Planas, “Unfractionated heparin is associated with a lower rise of serum vascular cell adhesion molecule-1 in acute ischemic stroke patients,” *Neuroscience Letters*, vol. 328, no. 3, pp. 229–232, 2002.
- [42] R. de Cock, L. A. Ficker, J. G. Dart, A. Garner, and P. Wright, “Topical heparin in the treatment of liginous conjunctivitis,” *Ophthalmology*, vol. 102, no. 11, pp. 1654–1659, 1995.
- [43] U. Derhaschnig, T. Pernerstorfer, M. Knechtelsdorfer, U. Hollenstein, S. Panzer, and B. Jilma, “Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia,” *Critical Care Medicine*, vol. 31, no. 4, pp. 1108–1112, 2003.
- [44] B. Dixon, M. J. Schultz, R. Smith, J. B. Fink, J. D. Santamaria, and D. J. Campbell, “Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial,” *Critical Care*, vol. 14, no. 5, article R180, 2010.
- [45] F. K. Keating, H. L. Dauerman, D. A. Whitaker, B. E. Sobel, and D. J. Schneider, “The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention,” *Coronary Artery Disease*, vol. 16, no. 6, pp. 401–405, 2005.
- [46] M. Ledson, M. Gallagher, C. A. Hart, and M. Walshaw, “Nebulized heparin in *Burkholderia cepacia* colonized adult cystic fibrosis patients,” *European Respiratory Journal*, vol. 17, no. 1, pp. 36–38, 2001.
- [47] D. J. Serisier, J. K. Shute, P. M. Hockey, B. Higgins, J. Conway, and M. P. Carroll, “Inhaled heparin in cystic fibrosis,” *European Respiratory Journal*, vol. 27, no. 2, pp. 354–358, 2006.
- [48] O. K. Poyrazoglu, A. Dogukan, M. Yalniz, D. Seckin, and A. L. Gunal, “Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients,” *Renal Failure*, vol. 28, no. 8, pp. 723–727, 2006.
- [49] S. Suzuki, T. Matsuo, H. Kobayashi et al., “Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters,” *Thrombosis Research*, vol. 98, no. 4, pp. 269–279, 2000.
- [50] S. D. Trocme and H.-I. Li, “Effect of heparin-surface-modified intraocular lenses on postoperative inflammation after phacoemulsification: a randomized trial in a United States patient population,” *Ophthalmology*, vol. 107, no. 6, pp. 1031–1037, 2000.
- [51] C. Vancheri, C. Mastruzzo, F. Armato et al., “Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis,” *Journal of Allergy and Clinical Immunology*, vol. 108, no. 5, pp. 703–708, 2001.
- [52] A. Abdollahi, M.-T. Naini, H. Shams, and R. Zarei, “Effect of low-molecular-weight heparin on postoperative inflammation in phacomorphic glaucoma,” *Archives of Iranian Medicine*, vol. 5, no. 4, pp. 225–229, 2002.
- [53] R. T. S. Lakshmi, T. Priyanka, J. Meenakshi, K. R. Mathangi, V. Jeyaraman, and M. Babu, “Low molecular weight heparin mediated regulation of nitric oxide synthase during burn wound healing,” *Annals of Burns and Fire Disasters*, vol. 24, no. 1, pp. 24–29, 2011.
- [54] G. Montalescot, C. Bal-dit-Sollier, D. Chibedi et al., “Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study),” *The American Journal of Cardiology*, vol. 91, no. 8, pp. 925–930, 2003.
- [55] S. Nasiripour, K. Gholami, S. Mousavi et al., “Comparison of the effects of enoxaparin and heparin on inflammatory biomarkers in patients with ST-segment elevated myocardial infarction: a prospective open label pilot clinical trial,” *Iranian Journal of Pharmaceutical Research*, vol. 13, no. 2, pp. 583–590, 2014.
- [56] J. Oldgren, C. Fellenius, K. Boman et al., “Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease,” *Journal of Internal Medicine*, vol. 258, no. 5, pp. 420–427, 2005.
- [57] T. K. Rudolph, V. Rudolph, A. Witte et al., “Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function,” *International Journal of Cardiology*, vol. 140, no. 1, pp. 42–47, 2010.
- [58] D. L. Walters, M. J. Ray, P. Wood, E. J. Perrin, J. H. N. Bett, and C. N. Aroney, “High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention,” *European Journal of Clinical Investigation*, vol. 40, no. 2, pp. 139–147, 2010.
- [59] S. W. Rathbun, C. E. Aston, and T. L. Whittsett, “A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis,” *Journal of Thrombosis and Haemostasis*, vol. 10, no. 5, pp. 833–839, 2012.
- [60] J. P. Titon, D. Auger, P. Grange et al., “Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with a non-steroidal anti-inflammatory agent,” *Annales de Cardiologie et d Angéiologie*, vol. 43, no. 3, pp. 160–166, 1994.
- [61] H. Uncu, “A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis,” *Phlebology*, vol. 24, no. 2, pp. 56–60, 2009.
- [62] J. A. Sjøland, R. S. Pedersen, J. Jespersen, and J. Gram, “Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients,” *Nephron—Clinical Practice*, vol. 100, no. 4, pp. c105–c110, 2005.
- [63] N. L. Fine, C. Shim, and M. H. Williams Jr., “Objective evaluation of heparin in the treatment of asthma,” *American Review of Respiratory Disease*, vol. 98, no. 5, pp. 886–887, 1968.

- [64] Z. Diamant, M. C. Timmers, H. van der Veen, C. P. Page, F. J. van der Meer, and P. J. Sterk, "Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma," *American Journal of Respiratory and Critical Care Medicine*, vol. 153, no. 6 I, pp. 1790–1795, 1996.
- [65] C. M. E. Tranfa, A. Vatrella, R. Parrella, G. Pelaia, F. Bariffi, and S. A. Marsico, "Effect of inhaled heparin on water-induced bronchoconstriction in allergic asthmatics," *European Journal of Clinical Pharmacology*, vol. 57, no. 1, pp. 5–9, 2001.
- [66] I. Stelmach, J. Jerzyńska, A. Brzozowska, and P. Kuna, "The effect of inhaled heparin on postleukotriene bronchoconstriction in children with asthma," *Polski Merkurusz Lekarski*, vol. 12, no. 68, pp. 95–98, 2002.
- [67] R. Polosa, S. Magri, C. Vancheri et al., "Time course of changes in adenosine 5'-monophosphate airway responsiveness with inhaled heparin in allergic asthma," *Journal of Allergy and Clinical Immunology*, vol. 99, no. 3, pp. 338–342, 1997.
- [68] J. Butler, G. M. Rocker, and S. Westaby, "Inflammatory response to cardiopulmonary bypass," *The Annals of Thoracic Surgery*, vol. 55, no. 2, pp. 552–559, 1993.
- [69] J. M. Redmond, A. M. Gillinov, R. S. Stuart et al., "Heparin-coated bypass circuits reduce pulmonary injury," *The Annals of Thoracic Surgery*, vol. 56, no. 3, pp. 474–479, 1993.
- [70] S. Svenmarker, E. Sandström, T. Karlsson et al., "Clinical effects of the heparin coated surface in cardiopulmonary bypass," *European Journal of Cardio-Thoracic Surgery*, vol. 11, no. 5, pp. 957–964, 1997.
- [71] Y. J. Gu, W. van Oeveren, C. Akkerman, P. W. Boonstra, R. J. Huyzen, and C. R. H. Wildevuur, "Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass," *The Annals of Thoracic Surgery*, vol. 55, no. 4, pp. 917–922, 1993.
- [72] D. Paparella, O. O. Al Radi, Q. H. Meng, T. Venner, K. Teoh, and E. Young, "The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass," *Blood Coagulation and Fibrinolysis*, vol. 16, no. 5, pp. 323–328, 2005.
- [73] S. Danese, A. Papa, S. Saibeni, A. Repici, A. Malesci, and M. Vecchi, "Inflammation and coagulation in inflammatory bowel disease: the clot thickens," *The American Journal of Gastroenterology*, vol. 102, no. 1, pp. 174–186, 2007.
- [74] S. Bloom, S. Kiilerich, M. R. Lassen et al., "Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis," *Alimentary Pharmacology & Therapeutics*, vol. 19, no. 8, pp. 871–878, 2004.
- [75] P. Libby, "Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization," *American Journal of Cardiology*, vol. 86, no. 8, 2000.
- [76] N. T. Mulvihill and J. B. Foley, "Inflammation in acute coronary syndromes," *Heart*, vol. 87, no. 3, pp. 201–204, 2002.
- [77] N. A. Jameson, W. V. Good, and C. S. Hoyt, "Inflammation after cataract surgery in children," *Ophthalmic Surgery*, vol. 23, no. 2, pp. 99–102, 1992.
- [78] R. M. Sinsky, P. A. Amin, and R. Lingua, "Cataract extraction and intraocular lens implantation in an infant with a monocular congenital cataract," *Journal of Cataract & Refractive Surgery*, vol. 20, no. 6, pp. 647–651, 1994.
- [79] A. van Ophoven, A. Heinecke, and L. Hertle, "Safety and efficacy of concurrent application of oral pentosan polysulfate and subcutaneous low-dose heparin for patients with interstitial cystitis," *Urology*, vol. 66, no. 4, pp. 707–711, 2005.



**Hindawi**

Submit your manuscripts at  
<http://www.hindawi.com>

